Validation Data Gallery
Tested Applications
| Positive FC detected in | human peripheral blood lymphocytes |
Recommended dilution
| Application | Dilution |
|---|---|
| This reagent has been pre-titrated and tested for flow cytometric analysis. The suggested use of this reagent is 10 µl per 10^6 cells in a 100 µl suspension or 10 µl per 100 µl of whole blood. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
PE-65156 targets CD154 in FC applications and shows reactivity with Human, Non-human primates samples.
| Tested Reactivity | Human, Non-human primates |
| Host / Isotype | Mouse / IgG1, kappa |
| Class | Monoclonal |
| Type | Antibody |
| Immunogen | human CD154 fusion protein 相同性解析による交差性が予測される生物種 |
| Full Name | CD40 ligand |
| Calculated molecular weight | 261 aa, 29 kDa |
| GenBank accession number | BC071754 |
| Gene Symbol | CD40 Ligand |
| Gene ID (NCBI) | 959 |
| RRID | AB_2883934 |
| Conjugate | PE Fluorescent Dye |
| Excitation/Emission maxima wavelengths | 496 nm, 565 nm / 578 nm |
| Form | Liquid |
| Purification Method | The purified antibody is conjugated with R-phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography. |
| UNIPROT ID | P29965 |
| Storage Buffer | PBS with 0.1% sodium azide. |
| Storage Conditions | Store at 2-8°C. Avoid exposure to light. Stable for one year after shipment. |
Background Information
The CD40 ligand (CD40L, TRAP, CD154), a member of the TNF superfamily of ligands, is expressed as either a 33-kd transmembrane homologue or 18-kd soluble form (sCD154). CD40L is primarily expressed on activated CD4+ T cells and on a small proportion of CD8+ T cells and platelets. It binds to CD40 on antigen-presenting cells (APC), which leads to many effects depending on the target cell type. It has been suggested that CD40/CD40L interactions regulate oxidative stress and affect various signaling pathways in both the immunological and the cardiovascular systems. The CD40/CD40L system is also involved in tumorigenesis. Its expression is tightly regulated, and abnormal levels of CD40L are associated with the pathogenesis of atheromatous plaque destabilization and thrombotic events. Multiple mutations in CD40LG gene have been identified that are associated with hyper-IgM immunodeficiency syndrome type 1.
Protocols
| Product Specific Protocols | |
|---|---|
| FC protocol for PE CD154 antibody PE-65156 | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |